A hydrogel that stays closed in acid and opens in the intestine — or in a tumor.
Before it ever meets the body, the hydrogel is synthesized and loaded so that its resting state is closed: a dense, low-water-content network holding the drug payload physically trapped between crosslinked polymer chains.
Anionic networks such as poly(acrylic acid) (PAA) or the Eudragit L/S family carry pendant carboxylic acid groups (–COOH, pKa ~4.5–6). Cationic networks such as chitosan instead carry primary amines that protonate at low pH. The choice of backbone sets which direction the gel swells: anionic gels swell as pH rises, cationic gels swell as pH falls.
Covalent or ionic crosslinks between chains define the maximum mesh size the network can reach even when fully ionized. Denser crosslinking gives tighter pH control and slower release; sparser crosslinking gives a larger dynamic range but a leakier "off" state.
The drug is loaded either during gelation (in-situ entrapment) or by soaking the pre-formed collapsed gel in a concentrated drug solution and letting it diffuse in, then collapsing the gel further to lock it in place.
Gastric fluid is one of the most hostile chemical environments in the body. A well-designed anionic coating uses this acidity as a feature, not a threat — staying protonated, uncharged, and closed for the ~1–3 hours of gastric residence.
At pH well below the polymer pKa, carboxylic acid groups remain protonated (–COOH), so the chains carry no net charge. Without electrostatic repulsion between chains, the network has no driving force to imbibe extra water, and it stays collapsed.
Many peptide and protein drugs, and some small molecules, are degraded by gastric acid and pepsin. A collapsed, protonated shell keeps the internal microenvironment away from the bulk gastric fluid, preserving the drug until it reaches friendlier territory.
This is the same chemistry behind classic enteric-coated tablets: Eudragit L100 and S100 are anionic methacrylic acid copolymers used industrially for exactly this acid-resistant, intestine-triggered behavior.
A collapsed mesh of ~5 nm is far smaller than most drug molecules' hydrodynamic radius — diffusion out is effectively blocked until the network swells.
Passage through the pylorus into the duodenum brings a sharp pH jump. As the surrounding fluid pH rises past the polymer's pKa, the pendant acid groups deprotonate, and the network begins to swell.
–COOH groups lose their proton to become –COO⁻. Neighboring chains now carry like negative charges and repel each other, while the newly charged groups also draw in water by osmosis — both effects push the network to expand.
Because Eudragit L100 and S100 differ mainly in methacrylic-to-methyl-methacrylate ratio, their pKa — and therefore the pH, and hence the gut location, at which they swell — can be tuned. Blending the two grades lets formulators aim release at a specific segment.
Swelling is continuous with pH, not a step function: the gel is partially swollen through the mid-pH range before reaching its fully open state, giving a soft release ramp rather than an abrupt burst.
Once ionization is substantial, the mesh size grows past the drug's hydrodynamic diameter, and release becomes governed by ordinary diffusion through an increasingly open, water-rich gel.
The same network that blocked diffusion at low pH now behaves like a loose, water-saturated sponge. Drug molecules, no longer sterically trapped, follow their concentration gradient outward into the surrounding intestinal fluid.
Release kinetics often follow Fickian diffusion once the mesh is fully open, but during the swelling transition itself, polymer chain relaxation can co-limit transport — so-called anomalous (non-Fickian) release — giving formulators another lever over the release profile.
Matching gel thickness, crosslink density, and pKa lets engineers target a release window of minutes to hours, tuned to where along the GI tract — or in what tissue — the drug should actually appear.
A 10–40× jump in mesh size over a ~1 pH unit range is what converts a slow chemical signal (pH) into a sharp, useful, location-specific release event.
The payoff of pH-responsive design is site-specific delivery: protecting a drug through the stomach and releasing it exactly where — intestine or tumor — it is needed, while sparing healthy tissue exposure.
By choosing a polymer pKa that matches duodenal, ileal, or colonic pH, formulators can aim drug release — anti-inflammatory agents for inflammatory bowel disease, for instance — directly at the diseased segment rather than dosing the whole gut uniformly.
Solid tumors are often mildly acidic (extracellular pH ~6.5–6.8) due to the Warburg effect: cancer cells favor aerobic glycolysis even with oxygen present, producing excess lactate that acidifies poorly-cleared tumor tissue relative to the ~7.4 pH of healthy blood and stroma.
A pH-responsive nanoparticle or hydrogel carrier tuned to swell around pH 6.5–6.8 stays closed in normal circulation and healthy tissue, then opens specifically inside the tumor niche — concentrating chemotherapy where it is needed and reducing exposure to healthy organs.
The same physical mechanism — protonation-state-dependent swelling — underlies both an intestinal-targeting enteric coating and a tumor-selective nanocarrier; only the pKa is retuned.
The table below summarizes the main polymer families used in pH-responsive drug delivery and where each is typically deployed.